-
1دورية أكاديمية
المؤلفون: James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Benjamin Van Hoorick, Sophie Steeland, Caroline T’joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, the ADAPT+ Study Group
المصدر: Frontiers in Neurology, Vol 14 (2024)
مصطلحات موضوعية: efgartigimod, myasthenia gravis, neonatal Fc receptor, FcRn, IgG recycling, antibody fragment, Neurology. Diseases of the nervous system, RC346-429
العلاقة: https://www.frontiersin.org/articles/10.3389/fneur.2023.1284444/fullTest; https://doaj.org/toc/1664-2295Test; https://doaj.org/article/1a89a0788ce640369ff168f37dc4e637Test
الإتاحة: https://doi.org/10.3389/fneur.2023.1284444Test
https://doaj.org/article/1a89a0788ce640369ff168f37dc4e637Test -
2
المؤلفون: James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Benjamin Van Hoorick, Sophie Steeland, Caroline T’joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, the ADAPT+ Study Group
مصطلحات موضوعية: Neurology and Neuromuscular Diseases, Neurogenetics, efgartigimod, myasthenia gravis, neonatal Fc receptor, FcRn, IgG recycling, antibody fragment, autoantibody reduction, neonatal Fc receptor antagonist
الإتاحة: https://doi.org/10.3389/fneur.2023.1284444.s003Test
https://figshare.com/articles/dataset/Table_2_Long-term_safety_tolerability_and_efficacy_of_efgartigimod_ADAPT_interim_results_from_a_phase_3_open-label_extension_study_in_participants_with_generalized_myasthenia_gravis_DOCX/25009859Test -
3صورة
المؤلفون: James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Benjamin Van Hoorick, Sophie Steeland, Caroline T’joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, the ADAPT+ Study Group
مصطلحات موضوعية: Neurology and Neuromuscular Diseases, Neurogenetics, efgartigimod, myasthenia gravis, neonatal Fc receptor, FcRn, IgG recycling, antibody fragment, autoantibody reduction, neonatal Fc receptor antagonist
الإتاحة: https://doi.org/10.3389/fneur.2023.1284444.s001Test
https://figshare.com/articles/figure/Image_1_Long-term_safety_tolerability_and_efficacy_of_efgartigimod_ADAPT_interim_results_from_a_phase_3_open-label_extension_study_in_participants_with_generalized_myasthenia_gravis_jpeg/25009853Test